CH
IBRX icon

CVI Holdings’s ImmunityBio IBRX Stock Holding History

CVI Holdings’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-226,916
Closed -$383K – 198
2023
Q3 		$383K Buy
+226,916
New +$456K 0.76% 29
2023
Q1 		– Sell
-7,609,166
Closed -$38.6M – 428
2022
Q4 		$38.6M Buy
+7,609,166
New +$41.8M 4.92% 1
2020
Q3 		– Sell
-787,863
Closed -$9.68M – 98
2020
Q2 		$9.68M Buy
+787,863
New +$4.45M 3.59% 10

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CVI Holdings's IBRX Position: Q4 2023 in Review

CVI Holdings sold out of ImmunityBio (IBRX) in Q4 2023, closing a stake of 226,916 shares — an estimated $383K sold.

CVI Holdings first reported a position in IBRX in Q2 2020 and held it in 3 quarters. The position peaked at $38.6M in Q4 2022. 147 funds tracked by Wall St. Rank hold IBRX as of Q4 2023.

  • CVI Holdings reported no remaining ImmunityBio position as of Q4 2023 after selling out during the quarter.
  • CVI Holdings sold 226,916 ImmunityBio shares in Q4 2023, an estimated $383K.
  • CVI Holdings first reported a position in ImmunityBio in Q2 2020 and held it in 3 quarters.
  • CVI Holdings's ImmunityBio position peaked at $38.6M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2023.

Based on CVI Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.